Short-term effects of ETI in pediatric cystic fibrosis patients in Brazil
Author Information
Author(s): Amor-Barbosa Marta, Vendrusculo Fernanda Maria, Epifanio Matias, Donadio Marcio Vinicius Fagundes, Pinto Leonardo Araujo
Primary Institution: Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
Hypothesis
What are the short-term effects of elexacaftor/tezacaftor/ivacaftor therapy in pediatric cystic fibrosis patients?
Conclusion
The study shows positive impacts of ETI therapy on lung function and symptom improvement in pediatric cystic fibrosis patients.
Supporting Evidence
- Patients showed significant improvements in lung function after starting ETI therapy.
- One patient experienced complete regression of nasal polyps.
- None of the patients reported adverse effects from the treatment.
Takeaway
This study looked at how a new treatment helped kids with cystic fibrosis breathe better and feel less sick.
Methodology
Case series of pediatric patients treated with ETI therapy, monitoring lung function and symptoms.
Potential Biases
Potential bias due to the small sample size and lack of control group.
Limitations
The study is based on a small number of cases and lacks long-term follow-up data.
Participant Demographics
Three pediatric patients with varying CFTR gene mutations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website